Journal of Substance Abuse Treatment
Volume 38, Issue 4 , Pages 384-393 , June 2010

Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffective disorder

  • Jill M. Williams, M.D.

      Affiliations

    • UMDNJ-Robert Wood Johnson Medical School
    • UMDNJ-School of Public Health
    • Corresponding Author InformationCorresponding author. UMDNJ-Robert Wood Johnson Medical School Division of Addiction Psychiatry 317 George Street, Suite 105 New Brunswick, NJ 08901-2008. Tel.: +1 732 235 4341; fax: +1 732 235 4277.
    • ,
  • Marc L. Steinberg, Ph.D.

      Affiliations

    • UMDNJ-Robert Wood Johnson Medical School
    • UMDNJ-School of Public Health
    • ,
  • Mia Hanos Zimmermann, M.P.H, C.T.T.S.

      Affiliations

    • UMDNJ-Robert Wood Johnson Medical School
    • ,
  • Kunal K. Gandhi, M.B.B.S., M.P.H.

      Affiliations

    • UMDNJ-Robert Wood Johnson Medical School
    • UMDNJ-School of Public Health
    • ,
  • Brooke Stipelman, Ph.D.

      Affiliations

    • National Cancer Institute
    • ,
  • Patricia Dooley Budsock, M.A., C.T.T.S.

      Affiliations

    • UMDNJ-Robert Wood Johnson Medical School
    • ,
  • Douglas M. Ziedonis, M.D., M.P.H.

      Affiliations

    • University of Massachusetts Medical School

Received 14 October 2009 ,Revised 4 February 2010 ,Accepted 9 March 2010.

References 

  1. Addington J, el-Guebaly N, Campbell W, Hodgins DC, Addington D. Smoking cessation treatment for patients with schizophrenia. American Journal of Psychiatry. 1998;155:974–976
  2. Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. American Journal of Psychiatry. 2006;163:1934
  3. Beck AT, Ward CH, Mendelson M. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:461–471
  4. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. British Journal of Psychiatry. 2000;177:212–217
  5. Covey LS, Hughes D, Glassman AH, Blazer D, George LK. Ever-smoking, quitting, and psychiatric disorders: Evidence from the Durham, North Carolina, Epidemiologic Catchment Area. Tobacco Control. 1994;3:222–227
  6. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings. American Journal of Psychiatry. 1998;155:1490–1501
  7. de Leon J, Diaz F. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and smoking behaviors. Schizophrenia Research. 2005;76:135–157
  8. Evins AE, Cather C, Rigotti NA, Freudenreich O, Henderson DC, Olm-Shipman CM, et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: Increased rates of smoking cessation and reduction. Journal of Clinical Psychiatry. 2004;65:307–311
  9. Fagerström KO, Hughes JR. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: A review. Nicotine and Tobacco Research. 2002;4(Suppl 2):S73–S79
  10. Fagerström KO, Tejding R, Westin A, Lunell E. Aiding reduction of smoking with nicotine replacement medications: Hope for the recalcitrant smoker?. Tobacco Control. 1997;6:311–316
  11. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry S, et al. Treating tobacco use and dependence: 2008 update. clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008;
  12. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12:189–198
  13. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biological Psychiatry. 2008;63:1092–1096
  14. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biological Psychiatry. 2002;52:53–61
  15. George T, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry. 2000;157:1835–1842
  16. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research. 2005;80:45–53
  17. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction. 1991;86:1119–1127
  18. Hitsman B, Moss TG, Montoya ID, George TP. Treatment of tobacco dependence in mental health and addictive disorders. Canadian Journal of Psychiatry. 2009;54:368–378
  19. Horvath AO, Greenberg L. Development and validation of the Working Alliance Inventory. Journal of Counseling Psychology. 1989;36:223–233
  20. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry. 1986;143:993–997
  21. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation. British Journal of Psychiatry. 1989;7:59–67
  22. Kleber HD, Weiss RD, Anton RF, Rounsaville BJ, George TP, Strain EC, et al. American Psychiatric Association, treatment of patients with substance use disorders, second edition. American Journal Psychiatry. 2006;163(8 Suppl):5–82
  23. Lasser K, Wesley BJ, Woolhandler S, Himmestein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. Journal of the American Medical Association. 2000;284:2606–2610
  24. Leslie DL, Rosenheck RA. Benchmarking the quality of schizophrenia pharmacotherapy: A comparison of the Department of Veterans Affairs and the private sector. Journal of Mental Health Policy and Economics. 2003;6:113–121
  25. McChargue DE, Gulliver SB, Hitsman B. Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment?. Addiction. 2002;97:785–793
  26. McLellan AT, Luborsky L, Woody GE, O ' Brien CP. An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index. Journal of Nervous and Mental Disease. 1980;168:26–33
  27. Montoya I, Vocci F. Medications development of the treatment of nicotine dependence in individuals with schizophrenia. Journal of Dual Diagnosis. 2007;3:113–150
  28. Sobell LC, Sobell MB. Alcohol Timeline Followback (TLFB) user's manual. Toronto, Canada: Addiction Research Foundation; 1996;
  29. Spitzer, R. L., & Williams, J. B. W. (1985). Structured Clinical Interview for DSM-III-R. New York: Biometrics Research Department, New York State Psychiatric Institute.
  30. Steinberg ML, Williams JM. Psychosocial treatments for individuals with schizophrenia and tobacco dependence. Journal of Dual Diagnosis. 2007;3:99–112
  31. Steinberg ML, Williams JM, Ziedonis DM. Financial implications of cigarette smoking among individuals with schizophrenia. Tobacco Control. 2004;13:206
  32. Steinberg ML, Ziedonis DM, Krejci JA, Brandon TH. Motivational interviewing with personalized feedback: A brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. Journal of Consulting and Clinical Psychology. 2004;72:723–728
  33. Strand J, Nybäck H. Tobacco use in schizophrenia: A study of cotinine concentrations in the saliva of patients and controls. European Psychiatry. 2005;20:50–54
  34. Stout RL, Wirtz PW, Carbonari JP, DelBoca FK. Ensuring balanced distribution of prognostic factors in treatment outcome research. Journal of Studies on Alcohol. 1994;12:70–75
  35. Williams JM, Gandhi KK, Foulds J, Steinberg MB, Lu SE, Masumova F, et al. No advantage for high dose compared to regular dose nicotine patch on short-term abstinence rates in schizophrenia. In: Oral Paper Session at the 13th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT). 2007;Austin, TX
  36. Williams JM, Gandhi KK, Steinberg ML, Foulds J, Ziedonis DM, Benowitz N. Higher nicotine and carbon monoxide levels in menthol cigarette smokers with and without schizophrenia. Nicotine and Tobacco Research. 2007;9:873–881
  37. Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz N. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophrenia Research. 2005;79:323–335
  38. Ziedonis DM, George TP. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and of neurobiological and clinical issues. Schizophrenia Bulletin. 1997;23:247–254
  39. Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine and Tobacco Research. 2008;10:1691–1715
  40. Ziedonis DM, Kosten TR, Glazer WM, Frances RJ. Nicotine dependence and schizophrenia. Hospital and Community Psychiatry. 1994;45:204–206
  41. Ziedonis DM, Stern R. Dual recovery therapy for schizophrenia and substance abuse. Psychiatric Annals. 2001;31:255–264
  42. Ziedonis DM, Trudeau K. Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model. Schizophrenia Bulletin. 1997;23:229–238

PII: S0740-5472(10)00067-X

doi: 10.1016/j.jsat.2010.03.006

Journal of Substance Abuse Treatment
Volume 38, Issue 4 , Pages 384-393 , June 2010

Article Tools